-
FDA Vote Signals Growing Access to Peptide Therapies Through Telehealth
A recent FDA advisory vote could pave the way for wider access to certain peptide therapies through telehealth platforms, potentially opening a significant new market for patients and providers.
-
FDA Advisory Panel Recommends Expanded Compounding Access for Six Peptides
An FDA advisory panel has voiced support for allowing pharmacy compounding of six specific peptides, marking a hopeful step toward broader patient access pending final approval.
-
Ascletis Receives FDA Clearance to Begin Phase I Trial of Once-Monthly Obesity Peptide ASC35
Ascletis has received FDA IND clearance to begin Phase I testing of ASC35, a once-monthly injectable dual GLP-1R/GIPR peptide agonist being developed for obesity treatment.
-
New Phase 1 Trial Launches to Study YL217 in Advanced Solid Tumors
A newly registered first-in-human study will evaluate YL217, an investigational peptide-based therapy, in patients with advanced solid tumors, marking an early but hopeful step in oncology research.
-
New Clinical Trial Explores Efgartigimod as Potential Treatment for Guillain-Barré Syndrome
A new study, dubbed GREAT, is investigating whether efgartigimod can offer a safe and effective treatment option for patients battling Guillain-Barré syndrome.
-
New Study to Explore How Retained Natural Insulin Production Supports Diabetes Health
A large new clinical study will investigate how retained endogenous insulin, measured through C-peptide, may benefit quality of life and health outcomes for people living with insulin-treated diabetes.
-
New Phase 2b Trial Launches to Explore Rezpegaldesleukin for Severe Alopecia Areata
A new Phase 2b study is underway to evaluate rezpegaldesleukin, a pegylated interleukin-2 peptide therapy, as a potential treatment for adults with severe to very severe alopecia areata.
-
TwoStep Therapeutics Secures $62.5M Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate
TwoStep Therapeutics has closed an oversubscribed $62.5 million Series A financing round and received FDA clearance to begin clinical trials for its first-in-class peptide-drug conjugate, marking a major step forward for the emerging therapeutic platform.
-
Teitur’s TT-P34 Peptide Shows Promising Early Results for Parkinson’s Disease
Teitur Trophics has reported encouraging early-stage data for TT-P34, an investigational peptide targeting Parkinson’s disease, marking a hopeful step forward in neurodegenerative research.
-
Peptide Therapy Shows Early Promise in Phase I Parkinson’s Trial
A peptide-based treatment has reportedly succeeded in early Phase I testing for Parkinson’s disease, marking an encouraging step toward new therapeutic options for patients.